Celecoxib decreases prostaglandin E2 concentrations in nipple aspirate fluid from high risk postmenopausal women and women with breast cancer

BMC Cancer

Volumn 6, Issue , 2006, Pages

  Sauter, Edward R ^a   Qin, Wenyi ^a   Schlatter, Lisa ^a   Hewett, John E ^b   Flynn, John T ^c  

^a University of Missouri   (United States)

^b UNIVERSITY OF MISSOURI   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; PROSTAGLANDIN E2; VITAMIN;

ADULT; ALTERNATIVE MEDICINE; ARTICLE; ASPIRATION; BLOOD SAMPLING; BREAST CANCER; CANCER RISK; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG WITHDRAWAL; EDEMA; FEMALE; HEART PALPITATION; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; INSOMNIA; MEDICAL RESEARCH; NIPPLE; POSTMENOPAUSE; PREDICTION; PROSTAGLANDIN SYNTHESIS INHIBITION; TREATMENT DURATION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ARRHYTHMIAS, CARDIAC; BODY FLUIDS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CYCLOOXYGENASE 2 INHIBITORS; DIARRHEA; DINOPROSTONE; DOSE-RESPONSE RELATIONSHIP, DRUG; EDEMA; FEMALE; HUMANS; MIDDLE AGED; NIPPLES; PATIENT DROPOUTS; POSTMENOPAUSE; PREMENOPAUSE; PYRAZOLES; RISK FACTORS; SULFONAMIDES;

EID: 33750631736     PISSN: 14712407     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-6-248     Document Type: Article

References (15)

1. Fisher B: Highlights from Drit National Surgical Adjuvant Breast: and Bowel Project studies in the treatment and prevention of breast cancer. CA Cancer J Clin 1999, 49(3):159-177.
2. Whittle BJ: Gastrointestinal effects of nonsteroidal anti-inflammatory drugs. Fundam Clin Pharmacol 2003, 17(3):301-313.
3. Masferrer JL, Leahy KM, Koki AT, Zweifel BS, Settle SL, Woerner BM, Edwards DA, Flickinger AG, Moore RJ, Seibert K: Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 2000, 60(5):1306-1311.
4. Taketo MM: Cyclooxygenase-2 inhibitors in tumorigenesis (Part II). J Natl Cancer Inst 1998, 90(21):1609-1620.
5. Fulton AM, Gimotty P, Alonsozana E, Dorsey R, Kundu N: Elevated prostaglandin E2 (PGE2) levels In human breast cancer are associated with poor long-term survival. Proc Am Assn Cancer Res 2000, 41:3660A.
6. Harris RE, Beebe-Dank J, Alshafie GA: Reduction In the risk of human breast cancer by selective cyclooxygenase-2 (COX-2) inhibitors. BMC Cancer 2006, 6:27.
7. Meagher EA: Balancing gastroprotection and cardioprotection with selective cyclo-oxygenase-2 inhibitors: clinical implications. Drug Saf 2003, 26(13):913-924.
8. Lanza-Jacoby S, Miller S, Flynn J, Gallatig K, Daskalakis C, Masferrer JL, Zweifel BS, Sembhi H, Russo IH: The cyclooxygenase-2 inhibitor, celecoxib, prevents the development of mammary tumors in Her-2/neu mice. Cancer Epidemiol Biomarkers Prev 2003, 12(12):1486-1491.
9. Alshafle G, Abou-Issa HM, Selbert K, Harris RE: Chemotherapeutic evaluation of celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, In a rat mammary tumor model. Proc Am Assn Cancer Res 2000, 41:3144A
10. Sauter ER, Ross E, Daly M, Klein-Szanto A, Engstrom PF, Sorling A, Malick J, Ehya H: Nipple aspirate fluid: a promising non-invasive method to identify cellular markers of breast cancer risk. Br J Cancer 1997, 76(4)494-501.
11. Sauter ER, Schlatter L, Hewett J, Kolvunen D, Flynn JT: Lack of effect of celecoxib on prostaglandin E2 concentrations in nipple aspirate fluid from women at Increased risk of breast cancer. Cancer Epidemiol Biomarkers Prev 2004, 13(11 Pt 1):1745-1750.
12. Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, Gordon GB, Wakabayashi N, Saunders B, Shen Y, Fujimura T, Su LK, Levin B: The effect of celecoxib, a cyclooxygenase-2 inhibitor, In famillial adenomatous polyposis. N Engl J Med 2000, 342(26):1946-1952.
13. Sauter ER, Daly M, Linahan K, Ehya H, Engstrom PF, Bonney G. Ross EA, Yu H, Diamandis E: Prostate-specific antigen levels in nipple aspirate fluid correlate with breast cancer risk. Cancer Epidemiol Biomarkers; Prev 1996, 5(12):967-970.
14. Hidalgo GE, Zhong L, Doherty DE, Hirschowitz EA: Plasma PGE-2 levels and altered cytokine profiles In adherent peripheral blood mononuclear cells in non-small cell lung cancer (NSCLC). Mol Cancer 2002, 1:5.
15. Harris RE, Alshafie GA, Abou-Issa H, Seibert K: Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor. Cancer Res 2000, 60(8):2101-2103.